Welcome to our dedicated page for Paysign news (Ticker: PAYS), a resource for investors and traders seeking the latest updates and insights on Paysign stock.
Paysign, Inc. reports developments in patient affordability programs, donor compensation solutions, engagement and management platforms, and integrated payment processing for the life sciences industries. The company operates at the intersection of fintech and healthcare, serving plasma, pharmaceutical and life sciences customers with payment and program-management technologies.
Recurring updates cover earnings results, patient affordability growth, pharmaceutical copay program performance, claims-processing activity, plasma donor compensation revenue, and SaaS engagement technologies for donor and program management. Company announcements also discuss Dynamic Business Rules for mitigating copay accumulators and maximizers, physical, virtual, mobile and bank-based payment capabilities, reporting and analytics, and investor conference participation.
Paysign (NASDAQ: PAYS) announced it will present at the 17th Annual Midwest IDEAS Investor Conference, held August 26-27, 2026, at the InterContinental in Chicago, Illinois. The invitation-only event connects public companies with institutional investors through one-on-one and group meetings.
Paysign will be represented by CEO Mark Newcomer, CFO Jeff Baker, and Matt Turner, President of Patient Affordability, who will be available for meetings. Paysign operates at the intersection of fintech and healthcare, providing payment processing, patient affordability solutions, and donor compensation programs for plasma, pharmaceutical and life sciences clients.
Paysign (NASDAQ:PAYS) reported record Q2 2026 revenue of $28.25 million, up 48.1% year over year. Pharma revenue rose 88.9% to $14.65 million, driven by 51 net new patient affordability programs over the past 12 months, while plasma revenue grew 21.4% to $13.04 million despite a 46-center decline to 561 centers.
Gross margin improved to 63.3% and operating margin reached 24.8%; excluding a $0.99 million non-cash fair value gain, operating margin was 21.3%. GAAP net income increased to $6.76 million ($0.11 diluted EPS) from $1.39 million. Adjusted EBITDA rose 113.0% to $9.61 million ($0.16 per diluted share). The company ended the quarter with $27.37 million of unrestricted cash and no bank debt.
According to Paysign, full-year 2026 guidance was raised to $114–$117 million revenue and $35–$38 million Adjusted EBITDA, with 2026 revenue growth expected at 39–43% and gross margin at 62–63%.
Paysign (NASDAQ: PAYS) will host its second quarter 2026 earnings call at 5:00 p.m. Eastern on Wednesday, August 5, 2026. The U.S. dial-in number is 877.407.2988 and the international dial-in number is +1.201.389.0923, with a live webcast also available.
A replay can be accessed by dialing 877.660.6853 (U.S.) or +1.201.612.7415 and entering Conference ID 13761445. According to Paysign, the replay will remain available until November 4, 2026. Financial professionals who wish to ask questions must email ir@paysign.com by 5:00 p.m. Eastern on Friday, July 31, 2026 to register.
Paysign (NASDAQ:PAYS) announced it will present at Planet MicroCap Las Vegas 2026, held June 16-18, 2026 at the Bellagio Resort & Casino. CFO Jeff Baker is scheduled to present on Wednesday, June 17 at 11:30 a.m. Pacific time.
Investors can visit the event website for details, registration, agenda and webcasts.
Paysign (NASDAQ:PAYS), a provider of patient affordability and donor compensation payment solutions, will present at the 20th Annual Barrington Research Virtual Spring Investment Conference on May 27, 2026. CFO Jeff Baker will hold one-on-one presentations, and investors can visit the event website for registration details.
Paysign (NASDAQ:PAYS) reported strong first quarter 2026 results, with revenue of $28.04 million, up 50.8% year over year. Pharma revenue rose 81.9% to $15.68 million and plasma revenue grew 24.9% to $11.75 million.
Operating margin expanded to 23.8% from 13.4%, while net income increased 110.3% to $5.44 million, or $0.09 per diluted share. Adjusted EBITDA rose 113.4% to $10.59 million. Paysign ended the quarter with $20.55 million in unrestricted cash and no bank debt. Full-year 2026 guidance calls for revenue of $106.5–$110.5 million, 30–35% growth, and net income of $13–$16 million.
Paysign (NASDAQ: PAYS) will host its first quarter 2026 earnings call at 5:00 p.m. ET on Tuesday, May 12, 2026. The company provided dial-in numbers, a webcast link, and replay details; the replay is available until August 12, 2026. Financial professionals wishing to ask questions must register by 5:00 p.m. ET on Friday, May 8, 2026 via email.
Paysign (NASDAQ: PAYS) reported strong 2025 results: $82.02M revenue (+40.5%), net income of $7.55M and Adjusted EBITDA $19.94M (+107.3%). Pharma revenue grew 167.8% and patient affordability programs rose to 131. Company exited 2025 with $21.07M unrestricted cash, $143.92M restricted cash and zero debt. 2026 guidance targets $106.5M–$110.5M revenue and $30M–$33M adjusted EBITDA.
Paysign (NASDAQ: PAYS) will host its fourth quarter and full year 2025 earnings call on Tuesday, March 24, 2026 at 5:00 p.m. ET. Investors can join via U.S. and international dial-ins or a live webcast. Replay is available through June 24, 2026.
Financial professionals who wish to ask questions must register by emailing ir@paysign.com by 5:00 p.m. ET on Friday, March 20, 2026.
Paysign (NASDAQ: PAYS) will present at the Oppenheimer 11th Annual Emerging Growth Conference, held February 3-4, 2026, in a virtual format. The conference features one-on-one and small-group meetings with emerging companies across technology, industrial growth and consumer sectors. Paysign’s CFO Jeff Baker will host one-on-one investor meetings on Tuesday, February 3, 2026. Investors interested in attending are instructed to contact their Oppenheimer representative to register.